Inventiva provides a corporate business update in the context of the COVID-19 pandemic
Daix (France), April 7, 2020 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today provided an update on its business activities and financial position as well as the initiatives announced to support its employees and the local community amid the evolving COVID-19 pandemic, all while promoting the continuity of essential work on the development of its R&D portfolio.
Employee update and initiatives to support local community
Following the recommendations of domestic public health authorities, Inventiva has implemented a series of measures to minimize risks for its employees and support their health and safety in this uncertain time. The Company has put on hold non-essential pre-clinical activities and implemented a work from home policy for most of its employees, including those engaged in research and development functions. Only a very limited presence is maintained on-site to enable the Company to quickly and efficiently restart full activities following the COVID-19 pandemic.
In addition, Inventiva supports the Dijon University Hospital as well as health care professionals in the region in the fight against COVID-19 by providing them with masks and protective gear.
As of today, no employees have been infected with COVID-19 to the knowledge of the Company.
Download PDF